DOCSLIB.ORG

TNF Decoy Receptors Encoded by Poxviruses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TNF Decoy Receptors Encoded by Poxviruses pathogens Review TNF Decoy Receptors Encoded by Poxviruses Francisco Javier Alvarez-de Miranda † , Isabel Alonso-Sánchez † , Antonio Alcamí and Bruno Hernaez * Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Campus de Cantoblanco, Universidad Autónoma de Madrid, Nicolás Cabrera 1, 28049 Madrid, Spain; [email protected] (F.J.A.-d.M.); [email protected] (I.A.-S.); [email protected] (A.A.) * Correspondence: [email protected]; Tel.: +34-911-196-4590 † These authors contributed equally. Abstract: Tumour necrosis factor (TNF) is an inflammatory cytokine produced in response to viral infections that promotes the recruitment and activation of leukocytes to sites of infection. This TNF- based host response is essential to limit virus spreading, thus poxviruses have evolutionarily adopted diverse molecular mechanisms to counteract TNF antiviral action. These include the expression of poxvirus-encoded soluble receptors or proteins able to bind and neutralize TNF and other members of the TNF ligand superfamily, acting as decoy receptors. This article reviews in detail the various TNF decoy receptors identified to date in the genomes from different poxvirus species, with a special focus on their impact on poxvirus pathogenesis and their potential use as therapeutic molecules. Keywords: poxvirus; immune evasion; tumour necrosis factor; tumour necrosis factor receptors; lymphotoxin; inflammation; cytokines; secreted decoy receptors; vaccinia virus; ectromelia virus; cowpox virus Citation: Alvarez-de Miranda, F.J.; Alonso-Sánchez, I.; Alcamí, A.; 1. TNF Biology Hernaez, B. TNF Decoy Receptors TNF is a potent pro-inflammatory cytokine with a broad range of biological effects, Encoded by Poxviruses. Pathogens ranging from the activation of inflammatory gene programs to cell differentiation or 2021, 10, 1065. https://doi.org/ apoptosis induction while also playing an essential role in the host control of many viral 10.3390/pathogens10081065 infections [1,2]. It was originally identified from the serum of animals treated with bacterial lipopolysaccharide (LPS) as a molecule that caused the necrosis of tumours in vivo, hence Academic Editors: Carlos its name. TNF is mainly secreted from activated macrophages, but also from natural Maluquer De Motes and killer and T-cells, neutrophils, eosinophils, mast cells and other non-immune cells, such as Antonieta Guerrero-Plata endothelial cells or neurons [3]. TNF is the best characterized member of the TNF ligand superfamily (TNFLSF), which includes 19 structurally related ligands that bind to type I Received: 22 June 2021 membrane glycoproteins at the cell surface, grouped as TNF receptor (TNFR) superfamily Accepted: 18 August 2021 (TNFRSF), to trigger TNFR signalling [4,5]. Published: 22 August 2021 TNF is first produced as a 26 kDa class II transmembrane protein (tmTNF) on the surface of cells. Then, tmTNF is cleaved by the metalloprotease TNF-converting enzyme Publisher’s Note: MDPI stays neutral (TACE) to be released as a soluble homotrimeric cytokine (sTNF) of about 51 kDa that can with regard to jurisdictional claims in execute its function far away from the site where it is synthesized [6]. published maps and institutional affil- iations. Far from just being a precursor, tmTNF is a key regulator for many immune and inflammatory processes, as both forms of TNF (tmTNF and sTNF) can bind to two different transmembrane cellular receptors with different affinities [7]. Whereas sTNF binds prefer- entially to the ubiquitous TNFR1 (also known as p55/p60), tmTNF is the main activating ligand for TNFR2 (also known as p75/p80), which is only expressed in certain endothelial Copyright: © 2021 by the authors. and immune cell types [8]. Both cell surface TNFRs are type I membrane glycoproteins Licensee MDPI, Basel, Switzerland. and similar in their extracellular domains involved in ligand binding, which comprise This article is an open access article four cysteine-rich domains (CRDs), each of them containing about 40 residues including distributed under the terms and conditions of the Creative Commons six conserved cysteines involved in the formation of internal disulfide bridges. The trans- Attribution (CC BY) license (https:// membrane domain of TNFRs is conserved through evolution and required for efficient creativecommons.org/licenses/by/ signalling [9]. Despite these similarities, TNFR1 and TNFR2 belong to different subgroups 4.0/). Pathogens 2021, 10, 1065. https://doi.org/10.3390/pathogens10081065 https://www.mdpi.com/journal/pathogens Pathogens 2021, 10, 1065 2 of 15 of the TNFRSF due to the differences in their intracellular signalling domains. The TNFR1 cytoplasmic domain harbours a death domain that enables direct interaction with the TNFR-associated death domain (TRADD) in response to TNF binding. The TNFR1-TRADD complex then serves as a docking platform to recruit diverse signalling proteins such as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1), that initiate apoptotic cell death via the caspase cascade. In contrast, the intracellular part of TNFR2 does not contain a death domain and promotes cell survival after TNF binding through recruitment of TNF receptor-associated proteins (TRAF) that trigger activation of transcription factor nuclear factor-kB (NF-kB). Activation of NF-κB may also occur after TNF stimulation via TNFR1, since the TRADD-TRAF2-RIPK1 complex can additionally serve as a scaffold for NF-κB essential modulator (NEMO) binding, which is essential for the inhibition of NF-kB kinase (IkB) degradation. In summary, TNF pro-survival action required for cell proliferation or Pathogens 2021, 10, 1065 differentiation can be executed either through TNFR1 or TNFR2, while TNF-mediated3 of 17 cell death mainly occurs through TNFR1 signalling (Figure1). B Soluble TNF/LTα blockade CrmB CrmC CrmB LTα CrmD TNF CrmD CrmE T2 vTNFBPs A TNFSF signalling TNFR1 TNFR2 DD D CD30L reverse signalling TRADD TRAF RIPK1 vCD30 CD30L NF-κB CrmB tmTNF Caspases Apoptosis CrmC Proliferation CrmD CrmE IL8 tmTNF Inflammation IFNγ C reverse signalling FigureFigure 1. 1.TNFTNF cellular cellular response response and viral and counteraction. viral counteraction. (A) TNF (A) signalling TNF signalling through intracellular through intracellular deathdeath domains domains (DD) (DD) in TNFR1 in TNFR1 recruits recruits TRADD TRADD and triggers and apoptotic triggers cell apoptotic death via cell RIPK1 death and via the RIPK1 and caspasesthe caspases cascade. cascade. In contrast, In contrast, prosurvival prosurvival action mediated action mediatedby TRAF and byTRAF NF-κB and can NF-be inducedκB can be induced through TNFR2 by either TNF or LTα. This second signalling cascade, leading to cell proliferation, canthrough also be TNFR2activated by by either TNFR1. TNF (B) orvTNFRs LTα. Thisand vTNFBPs second signalling differentially cascade, bind and leading block toTNF cell and proliferation, LTαcan to also prevent be activated cytokine binding by TNFR1. to cognate (B) vTNFRs cellular and receptors. vTNFBPs (C) vTNFRs differentially CrmB, bind CrmC, and CrmD block and TNF and LTα CrmEto prevent can also cytokine promote binding reverse tosignalling cognate through cellular tmTNF receptors. at the (C) cell vTNFRs surface CrmB,and dampen CrmC, inflam- CrmD and CrmE mation.can also (D) promote vCD30 also reverse induces signalling reverse signalling through tmTNF through at CD30L, the cell causing surface inhibition and dampen of IFNγ inflammation. and (D) expression of IL8. vCD30 also induces reverse signalling through CD30L, causing inhibition of IFNγ and expression of IL8. TNF Antiviral Activity Soluble versions of TNFR1 and TNFR2 may also exist as a result of alternative splicing or proteolyticOne of the main cleavage physiological [10,11]. roles To regulate of TNF TNFis the biologicalmediation of activity, acute inflammation these soluble variants during virus infection. TNF is locally induced early after virus infection and enhances its inhibit TNF by competing for its binding with their membrane bound counterparts, thus own expression together with other pro-inflammatory cytokines and also the secretion of chemokinesacting as that decoy promote receptors. the recruitment Similarly, and soluble activation receptors of leukocytes. have In been animal described models for other ofmembers infection, TNF, of the synergistically TNFLSF such with as interferon decoy receptor (IFN) γ, 1has (DcR1) been shown which to competes interfere with for TRAIL or thedecoy replication receptor of diverse 3 (DcR3) viruses, which such binds as hepatitis FasL, LIGHTB virus [25] and or TL1A murine [12 cytomegalovirus–14]. [26], amongIn addition, others. tmTNF can induce reverse signalling, a process by which this membrane- boundThe specific cytokine relevance can also of actTNF as and a receptorTNF signalling and trigger in the protection intracellular against signalling poxvirus in tmTNF- infectionsbearing is cells. also Thislargely tmTNF-elicited known and supported reverse by signalling experimental is key data for from the activation in vivo studies. and regulation Forof instance, T cells, macrophagesmouse strains naturally and natural resistant killer to (NK)a lethal cells poxvirus [15,16 infection,]. such as ectro- melia virusAnother (ECTV), TNFLSF became member more susceptible is lymphotoxin- after TNFRα (LTdeletion,α), the since closest 60% of homolog the knock- to TNF with out51% animals sequence succumbed similarity, to infection which mainly [27]. Indeed, exists treatment
Load more

Recommended publications
  • JOURNAL of VIROLOGY Volume 18 Contents for May Number 2
    JOURNAL OF VIROLOGY Volume 18 Contents for May Number 2 Animal Viruses Isolation and Properties of the Replicase of Encephalomyocarditis Virus. A. TRAUB,* B. DISKIN, H. ROSENBERG, AND E. KALMAR ...... ............... 375 Synthesis and Integration of Viral DNA in Chicken Cells at Different Times After Infection with Various Multiplicities of Avian Oncornavirus. ALLAN T. KHOURY* AND HIDESABURO HANAFUSA ........ .......................... 383 RNA Metabolism of Murine Leukemia Virus. III. Identification and Quantitation of Endogenous Virus-Specific mRNA in the Uninfected BALB/c Cell Line JLS-V9. HUNG FAN AND NIKOLAUS MUELLER-LANTZSCH* ..... ............ 401 Endogenous Ecotropic Mouse Type C Viruses Deficient in Replication and Produc- tion of XC Plaques. ULF W RAPP AND ROBERT C. NoWINSKI* ..... ....... 411 Further Characterization of the Friend Murine Leukemia Virus Reverse Tran- scriptase-RNase H Complex. KARIN MOELLING ...... ................... 418 State of the Viral DNA in Rat Cells Transformed by Polyoma Virus. I. Virus Res- cue and the Presence of Nonintegrated Viral DNA Molecules. ISHWARI PRASAD, DIMITRIS ZOUZIAS, AND CLAUDIO BASIUCO* ...... ................ 436 Inhibition of Infectious Rous Sarcoma Virus Production by a Rifamycin Deriva- tive. CHARLES SZABO,* MINA J. BISSELL, AND MELVIN CALVIN ..... ...... 445 Synthesis ofthe Adenovirus-Coded DNA Binding Protein in Infected Cells. ZVEE GILEAD,* KINJI SUGUWARA, G. SHANMUGAM, AND MAURICE GREEN ....... 454 Intracellular Distribution and Sedimentation Properties of Virus-Specific RNA in Two Clones of BHK Cells Transformed by Polyoma Virus. IAN H. MAX- WELL .............................................................. 461 Inherited Resistance to N- and B-Tropic Murine Leukemia Viruses In Vitro: Titration Patterns in Strains SIM and SIM.R Congenic at the Fv-1 Locus. VERA SCHUH, MARTIN E. BLACKSTEIN, AND ARTHUR A.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Dimerization of Ltβr by Ltα1β2 Is Necessary and Sufficient for Signal
    Dimerization of LTβRbyLTα1β2 is necessary and sufficient for signal transduction Jawahar Sudhamsua,1, JianPing Yina,1, Eugene Y. Chiangb, Melissa A. Starovasnika, Jane L. Groganb,2, and Sarah G. Hymowitza,2 Departments of aStructural Biology and bImmunology, Genentech, Inc., South San Francisco, CA 94080 Edited by K. Christopher Garcia, Stanford University, Stanford, CA, and approved October 24, 2013 (received for review June 6, 2013) Homotrimeric TNF superfamily ligands signal by inducing trimers survival in a xenogeneic human T-cell–dependent mouse model of of their cognate receptors. As a biologically active heterotrimer, graft-versus-host disease (GVHD) (11). Lymphotoxin(LT)α1β2 is unique in the TNF superfamily. How the TNFRSF members are typically activated by TNFSF-induced three unique potential receptor-binding interfaces in LTα1β2 trig- trimerization or higher order oligomerization, resulting in initiation ger signaling via LTβ Receptor (LTβR) resulting in lymphoid organ- of intracellular signaling processes including the canonical and ogenesis and propagation of inflammatory signals is poorly noncanonical NF-κB pathways (2, 3). Ligand–receptor interactions α β understood. Here we show that LT 1 2 possesses two binding induce higher order assemblies formed between adaptor motifs in sites for LTβR with distinct affinities and that dimerization of LTβR the cytoplasmic regions of the receptors such as death domains or α β fi by LT 1 2 is necessary and suf cient for signal transduction. The TRAF-binding motifs and downstream signaling components such α β β crystal structure of a complex formed by LT 1 2,LT R, and the fab as Fas-associated protein with death domain (FADD), TNFR1- fragment of an antibody that blocks LTβR activation reveals the associated protein with death domain (TRADD), and TNFR-as- lower affinity receptor-binding site.
    [Show full text]
  • The Unexpected Role of Lymphotoxin Β Receptor Signaling
    Oncogene (2010) 29, 5006–5018 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The unexpected role of lymphotoxin b receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development MJ Wolf1, GM Seleznik1, N Zeller1,3 and M Heikenwalder1,2 1Department of Pathology, Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland and 2Institute of Virology, Technische Universita¨tMu¨nchen/Helmholtz Zentrum Mu¨nchen, Munich, Germany The cytokines lymphotoxin (LT) a, b and their receptor genesis. Consequently, the inflammatory microenviron- (LTbR) belong to the tumor necrosis factor (TNF) super- ment was added as the seventh hallmark of cancer family, whose founder—TNFa—was initially discovered (Hanahan and Weinberg, 2000; Colotta et al., 2009). due to its tumor necrotizing activity. LTbR signaling This was ultimately the result of more than 100 years of serves pleiotropic functions including the control of research—indeed—the first observation that tumors lymphoid organ development, support of efficient immune often arise at sites of inflammation was initially reported responses against pathogens due to maintenance of intact in the nineteenth century by Virchow (Balkwill and lymphoid structures, induction of tertiary lymphoid organs, Mantovani, 2001). Today, understanding the underlying liver regeneration or control of lipid homeostasis. Signal- mechanisms of why immune cells can be pro- or anti- ing through LTbR comprises the noncanonical/canonical carcinogenic in different types of tumors and which nuclear factor-jB (NF-jB) pathways thus inducing cellular and molecular inflammatory mediators (for chemokine, cytokine or adhesion molecule expression, cell example, macrophages, lymphocytes, chemokines or proliferation and cell survival.
    [Show full text]
  • Escherichia Coli Saccharomyces Cerevisiae Bacillus Subtilis はB
    研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止措 置等を定める省令の規定に基づき認定宿主ベクター系等を定める件 （平成十六年一月二十九日文部科学省告示第七号） 最終改正：令和三年二月十五日文部科学省告示第十三号 （認定宿主ベクター系） 第一条 研究開発等に係る遺伝子組換え生物等の第二種使用等に当たって執るべき拡散防止 措置等を定める省令（以下「省令」という。）第二条第十三号の文部科学大臣が定める認 定宿主ベクター系は、別表第一に掲げるとおりとする。 （実験分類の区分ごとの微生物等） 第二条 省令第三条の表第一号から第四号までの文部科学大臣が定める微生物等は、別表第 二の上欄に掲げる区分について、それぞれ同表の下欄に掲げるとおりとする。 （特定認定宿主ベクター系） 第三条 省令第五条第一号ロの文部科学大臣が定める特定認定宿主ベクター系は、別表第一 の２の項に掲げる認定宿主ベクター系とする。 （自立的な増殖力及び感染力を保持したウイルス及びウイロイド） 第四条 省令別表第一第一号ヘの文部科学大臣が定めるウイルス及びウイロイドは、別表第 三に掲げるとおりとする。 別表第１（第１条関係） 区 分 名 称 宿主及びベクターの組合せ １ Ｂ１ (１) ＥＫ１ Escherichia coli K12株、B株、C株及びW株又は これら各株の誘導体を宿主とし、プラスミド又は バクテリオファージの核酸であって、接合等によ り宿主以外の細菌に伝達されないものをベクター とするもの（次項(１)のＥＫ２に該当するものを除 く。） (２) ＳＣ１ Saccharomyces cerevisiae又はこれと交雑可能な 分類学上の種に属する酵母を宿主とし、これらの 宿主のプラスミド、ミニクロモソーム又はこれら の誘導体をベクターとするもの（次項(２)のＳＣ２ に該当するものを除く。） (３) ＢＳ１ Bacillus subtilis Marburg168株、この誘導体又 はB. licheniformis全株のうち、アミノ酸若しく は核酸塩基に対する複数の栄養要求性突然変異を 有する株又は胞子を形成しない株を宿主とし、こ れらの宿主のプラスミド（接合による伝達性のな いものに限る。）又はバクテリオファージの核酸 をベクターとするもの（次項(３)のＢＳ２に該当す るものを除く。） (４) Thermus属細菌 Thermus属細菌（T. thermophilus、T. aquaticus、 T. flavus、T. caldophilus及びT. ruberに限る。） を宿主とし、これらの宿主のプラスミド又はこの 誘導体をベクターとするもの (５) Rhizobium属細菌 Rhizobium属細菌（R. radiobacter（別名Agroba- cterium tumefaciens）及びR. rhizogenes（別名 Agrobacterium rhizogenes）に限る。）を宿主と し、これらの宿主のプラスミド又はRK2系のプラ スミドをベクターとするもの (６) Pseudomonas putida Pseudomonas putida KT2440株又はこの誘導体を 宿主とし、これら宿主への依存性が高く、宿主以 外の細胞に伝達されないものをベクターとするも の (７) Streptomyces属細菌 Streptomyces属細菌（S. avermitilis、S. coel- icolor [S. violaceoruberとして分類されるS. coelicolor A3(２)株を含む]、S. lividans、S. p- arvulus、S. griseus及びS.
    [Show full text]
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • The Function of CD27 Costimulation in the Activation and Fate Decisions of CD8+ T Cells
    The function of CD27 costimulation in the activation and fate decisions of CD8+ T cells Han Dong Zhengzhou, Henan Province, China B.Sc, Zhejing University, 2009 A Dissertation presented to the Graduate Faculty of the University of Virginia in Candidacy for the Degree of Doctor of Philosophy Department of Experimental Pathology University of Virginia May 2015 ! i! Abstract CD8+ cytotoxic T lymphocytes are critical components of adaptive immunity against a variety of intracellular pathogens, and can play a key role in the control of tumors. Effective vaccination strategies against viral infections and tumors will likely require the development of potent CD8+ T cell responses, which are constituted by the expansion of robust primary CD8+ T cell populations and the establishment of long-lasting memory. Fully functional CD8+ T cell responses are highly dependent upon CD4+ helper T cells and Signal 3 inflammatory cytokine pathways. CD4+ T cells have been demonstrated to play a critical role in inducing the expression of CD70, the ligand for CD27, on dendritic cells. However, it is not clear to what extent the ‘help’ provided by CD4+ T cells is manifest via CD70, or how CD70-mediated stimulation of CD8+ T cells is integrated with signals that emanate from Signal 3 pathways, such as type-1 interferon (IFN-1) and IL- 12. In this work, by enforcing or abrogating CD27 function by genetic or protein intervention in murine models, we sought to identify the function of CD27 costimulation in the activation and fate decisions of CD8+ T cells, to determine the extent it resembles CD4+ T cell help, and how inflammation impacts the relative importance of CD70-CD27 interactions in CD8+ T cell primary responses and CD8+ T cell memory.
    [Show full text]
  • Comprehensive Product List
    Catalog # Product Description Retail Price OEM Price 1007 Antibody IL-1R associated kinase 225/100ug 125/100ug 1009 Antibody HIV & chemokine receptor 225/100ug 125/100ug 1012 Antibody HIV & chemokine receptor 225/100ug 125/100ug 1021 Antibody JAK activated transcription 225/100ug 125/100ug 1107 Antibody Tyrosine kinase substrate p62DOK 225/100ug 125/100ug 1112 Antibody HIV & chemokine receptor 225/100ug 125/100ug 1113 Antibody Ligand for DR4 and DR5 225/100ug 125/100ug 1115 Antibody Adapter Molecule 225/100ug 125/100ug 1117 Antibody Adapter Molecule 225/100ug 125/100ug 1120 Antibody Cell Death Receptor 225/100ug 125/100ug 1121 Antibody Ligand for GFRa-2 225/100ug 125/100ug 1123 Antibody CCR3 ligand 225/100ug 125/100ug 1125 Antibody Tyrosine kinase substrate 225/100ug 125/100ug 1128 Antibody A new caspase 225/100ug 125/100ug 1129 Antibody NF-kB inducing kinase 225/100ug 125/100ug 1131 Antibody TNFa converting enzyme 225/100ug 125/100ug 1133 Antibody GDNF receptor 225/100ug 125/100ug 1135 Antibody Neurturin receptor 225/100ug 125/100ug 1137 Antibody Persephin receptor 225/100ug 125/100ug 1139 Antibody Death Receptor for TRAIL 225/100ug 125/100ug 1141 Antibody DNA fragmentation factor & Inhibitor of CAD 225/100ug 125/100ug 1148 Antibody DNA fragmentation factor & Inhibitor of CAD 225/100ug 125/100ug 1150 Antibody Activator of MAPK pathway 225/100ug 125/100ug 1151 Antibody Apoptosis Signal-regulation Kinase 225/100ug 125/100ug 1156 Antibody FLICE inhibitory protein 225/100ug 125/100ug 1158 Antibody Cell Death Receptor 225/100ug 125/100ug 1159
    [Show full text]
  • CD95 Ligand - Death Factor and Costimulatory Molecule?
    Cell Death and Differentiation (2003) 10, 1215–1225 & 2003 Nature Publishing Group All rights reserved 1350-9047/03 $25.00 www.nature.com/cdd Review CD95 ligand - death factor and costimulatory molecule? O Janssen*,1, J Qian1, A Linkermann1 and D Kabelitz1 Tissue and Cellular Expression of CD95L 1 Institute for Immunology, Medical Center Schleswig-Holstein, Campus Kiel, Michaelisstrasse 5, D-24105 Kiel, Germany The CD95 ligand (CD95L, Apo-1L, FasL, CD178) is a 281- * Corresponding author: O Janssen. Tel: þ 49-431-5973377; Fax: þ 49-431- amino-acid-containing type II transmembrane protein of the 5973335; E-mail: [email protected] TNF family of death factors (Figure 1).1 Its death-inducing function is best documented in the context of activation- Received 24.4.03; revised 12.6.03; accepted 20.6.03; published online 1 August 2003 induced cell death (AICD) in T cells.2 CD95L is expressed as a Edited by T Ferguson death factor in cytotoxic T lymphocytes (CTL) to kill virally infected or transformed target cells and in natural killer (NK) cells, where it is upregulated by CD16 engagement and 3 Abstract cytokines including IL-2 and IL-12. Similarly, high levels of intracellular CD95L have been detected in monocytic cells The CD95 ligand is involved as a death factor in the with an inducible release upon activation.4 Under physiologi- regulation of activation-induced cell death, establishment cal conditions, CD95L is implicated in the control of erythroid of immune privilege and tumor cell survival. In addition, differentiation,5 angiogenesis in the eye6 and skin home- 7 CD95L may serve as a costimulatory molecule for T-cell ostasis.
    [Show full text]
  • Due to Interleukin-6 Type Cytokine Redundancy Only Glycoprotein 130 Receptor Blockade Efficiently Inhibits Myeloma Growth
    Plasma Cell Disorders SUPPLEMENTARY APPENDIX Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth Renate Burger, 1 Andreas Günther, 1 Katja Klausz, 1 Matthias Staudinger, 1 Matthias Peipp, 1 Eva Maria Murga Penas, 2 Stefan Rose-John, 3 John Wijdenes 4 and Martin Gramatzki 1 1Division of Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany; 2Institute of Human Genetics, Christian-Albrechts-University Kiel and Uni - versity Medical Center Schleswig-Holstein, Kiel, Germany; 3Department of Biochemistry, Christian-Albrechts-University of Kiel, Medical Faculty, Germany and 4Gen-Probe/Diaclone SAS, Besançon, France ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2016.145060 Received: February 25, 2016. Accepted: September 14, 2016. Pre-published: September 22, 2016. Correspondence: [email protected] SUPPLEMENTARY METHODS Cell lines and culture Cell lines INA-6, INA-6.Tu1 and B9 were cultivated in RPMI-1640 with GlutaMax™-I, 25 mM HEPES (Gibco®/Life Technologies GmbH, Darmstadt, Germany), 10% (v/v) heat-inactivated fetal bovine serum (FBS) (HyClone; Perbio Science, Erembodegen, Belgium), and antibiotics (R10+ medium) supplemented with 2.5 ng/ml recombinant huIL-6 (Gibco®/Life Technologies GmbH, Darmstadt, Germany). The cell lines are routinely confirmed to be negative for mycoplasma contamination (Venor™GeM Mycoplasma Detection Kit, Sigma-Aldrich, St. Louis, MO). Cytokines and other reagents Recombinant huIL-6 was purchased from Gibco®/Life Technologies (Darmstadt, Germany), huLIF was from Reliatech (Wolfenbüttel, Germany). Recombinant muIL-6 was obtained from Peprotech (Rocky Hill, NJ), and soluble muIL-6R was from R&D Systems (Minneapolis, MN).
    [Show full text]
  • Decoy Strategies: the Structure of TL1A:Dcr3 Complex
    Structure Article Decoy Strategies: The Structure of TL1A:DcR3 Complex Chenyang Zhan,1 Yury Patskovsky,1 Qingrong Yan,2 Zhenhong Li,1 Udupi Ramagopal,1 Huiyong Cheng,1 Michael Brenowitz,1 Xiao Hui,3 Stanley G. Nathenson,2,4 and Steven C. Almo1,5,* 1Department of Biochemistry 2Department of Cell Biology 3Department of Developmental and Molecular Biology 4Department of Microbiology and Immunology 5Department of Physiology and Biophysics Albert Einstein College of Medicine, Bronx, NY 10461, USA *Correspondence: [email protected] DOI 10.1016/j.str.2010.12.004 SUMMARY domains (CRDs), which bind the interprotomer grooves formed between adjacent ligand monomers. This mode of interaction Decoy Receptor 3 (DcR3), a secreted member of the results in ligand:receptor assemblies with 3:3 stoichiometries Tumor Necrosis Factor (TNF) receptor superfamily, that span two interacting cells. The ligand-mediated clustering neutralizes three different TNF ligands: FasL, LIGHT, of TNFRs directs the recruitment of signaling adaptor proteins, and TL1A. Each of these ligands engages unique such as TNF receptor associated factors (TRAFs) or death signaling receptors which direct distinct and critical domain adaptor proteins, and initiates diverse downstream immune responses. We report the crystal structures signaling pathways. Some TNFRs are also produced as soluble forms due to alter- of the unliganded DcR3 ectodomain and its complex nate mRNA splicing or selective proteolytic cleavage (Cheng with TL1A, as well as complementary mutagenesis et al., 1994; Locksley et al., 2001; Van Zee et al., 1992). The met- and biochemical studies. These analyses demon- alloprotease-mediated cleavage of two TNF-a receptors (TNFR1 strate that DcR3 interacts with invariant backbone and TNFR2) has been reported to attenuate proinflammatory and side-chain atoms in the membrane-proximal TNF-a-associated signaling, possibly by reducing the amount half of TL1A which supports recognition of its three of cell surface receptors and by the sequestration/neutralization distinct TNF ligands.
    [Show full text]
  • ICTV Code Assigned: 2011.001Ag Officers)
    This form should be used for all taxonomic proposals. Please complete all those modules that are applicable (and then delete the unwanted sections). For guidance, see the notes written in blue and the separate document “Help with completing a taxonomic proposal” Please try to keep related proposals within a single document; you can copy the modules to create more than one genus within a new family, for example. MODULE 1: TITLE, AUTHORS, etc (to be completed by ICTV Code assigned: 2011.001aG officers) Short title: Change existing virus species names to non-Latinized binomials (e.g. 6 new species in the genus Zetavirus) Modules attached 1 2 3 4 5 (modules 1 and 9 are required) 6 7 8 9 Author(s) with e-mail address(es) of the proposer: Van Regenmortel Marc, [email protected] Burke Donald, [email protected] Calisher Charles, [email protected] Dietzgen Ralf, [email protected] Fauquet Claude, [email protected] Ghabrial Said, [email protected] Jahrling Peter, [email protected] Johnson Karl, [email protected] Holbrook Michael, [email protected] Horzinek Marian, [email protected] Keil Guenther, [email protected] Kuhn Jens, [email protected] Mahy Brian, [email protected] Martelli Giovanni, [email protected] Pringle Craig, [email protected] Rybicki Ed, [email protected] Skern Tim, [email protected] Tesh Robert, [email protected] Wahl-Jensen Victoria, [email protected] Walker Peter, [email protected] Weaver Scott, [email protected] List the ICTV study group(s) that have seen this proposal: A list of study groups and contacts is provided at http://www.ictvonline.org/subcommittees.asp .
    [Show full text]